The FDA seems to have short memory. Other drugs that lower cholesterol either have no effect on CHD mortality or actually cause an increase in all-cause mortality. The only reasons that statins have any benefit (and it is very small one) in secondary prevention of CHD is that they are also anti-inflammatory drugs like aspirin. I can only imagine what the FDA will do if there is no improvement of CHD mortality as opposed the soft end points favored by the drug companies. In the meantime, billions will be likely spent on worthless drugs.
Dr. Sears Comments: